Chiquita Brooks-LaSure, Centers for Medicare and Medicaid Services administrator (Evan Vucci/AP Images)

April 3, 2023 06:48 AM EDTUpdated April 6, 02:02 AM

Whoops: CMS quietly pares back list of drugs requiring new rebates under Inflation Reduction Act

Zachary Brennan

Senior Editor

To discourage rapid drug price increases, the Inflation Reduction Act requires pharma companies that raise certain drug prices faster than the rate of inflation to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Whoops: CMS quietly pares back list of drugs requiring new rebates under Inflation Reduction Act

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Whoops: CMS qui­et­ly pares back list of drugs re­quir­ing new re­bates un­der In­fla­tion Re­duc­tion Act

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Whoops: CMS quietly pares back list of drugs requiring new rebates under Inflation Reduction Act